Kyowa Hakko Kirin Emphasizes Efforts On Kidney Disease With DPP-4
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin President Nobuo Hanai announced July 27 at a financial results briefing in Tokyo that the company will continue to provide a wide range of products targeting chronic kidney disease, with focus on renal anemia drugs NESP and ESPO.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.